Cellectar Biosciences, Inc. announced resignation of Chad J. Kolean as Vice President, Chief Financial Officer and Treasurer of the Company, effective September 5, 2017. The company appointed Mr. John P. Hamill as Interim Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.11 USD | +1.63% | -5.76% | +12.27% |
14/05 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.27% | 111M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar Biosciences, Inc. Announces Management Changes